OneSkin

OneSkin is a biotechnology company that develops scientifically backed skin longevity treatments. The company's technology centers around its proprietary peptide OS-01, which is clinically proven to reduce the skin's biological age by preventing the accumulation of senescent cells, a major driver of aging. Through its OS-01 FACE and OS-01 BODY product lines, OneSkin delivers topical supplements that target aging at the molecular level. The products contain key ingredients like pracaxi oil, andiroba oil, niacinamide, oleic pau mulato extract, allantoin, and hyaluronic acid alongside the OS-01 peptide. The products also work by decreasing inflammatory factors from senescent cells while preventing healthy cells from becoming senescent, leading to improved skin barrier function, increased collagen production, and enhanced hyaluronic acid synthesis.

In clinical testing, OS-01 demonstrated a reduction in senescent cells by 24%–40% across all age groups, skin colors, genders, and skin types. Through its proprietary MolClock technology, OneSkin became the first company to replicate skin aging in laboratory conditions to validate the skin's biological age reversal capabilities of its peptide at the cellular level. The company operates end-to-end R&D in-house with expertise spanning stem cell biology, skin regeneration, tissue engineering, biochemistry, bioinformatics, molecular biology, immunology, and aging.

In May 2024, the company expanded its product line with the launch of OS-01 Body SPF, a daily sunscreen formulated with non-nano zinc oxide and the OS-01 peptide.